BiOM® Changes Name to BionX™ - Gilde Healthcare

BiOM® Changes Name to BionX™

27. September 2015

New Name Highlights Company’s Core Competency in the Prosthetic Device Market

BEDFORD, Mass — iWalk (also known as BiOM®), a leader in the field of bionic prosthetic devices, announced today that the company has relaunched itself as BionX™ Medical Technologies, Inc. to better reflect its commitment to delivering bionic solutions that address critical unmet needs in the market. The company will unveil its new name and logo during its presentation at the Ladenburg Thalmann Healthcare Conference in New York City on Tuesday, September 29th. The corporate relaunch also reflects a series of significant company milestones, including the addition of an industry-leading executive team, market-leading product enhancements, international commercial expansion and ongoing support from reimbursement authorities such as the U.S. Department of Veterans Affairs and Workers’ Compensation payers across the U.S.

 “Our company was founded to revolutionize the prosthetic device industry by providing products, based on our bionic platform, that enable patients to have more freedom in their lives. Over the last year, we have made significant progress towards achieving this goal, having fortified our corporate organization, disciplined our commercial execution and continually expanded our IP portfolio and product pipeline,” said Dr. Charles S. Carignan, President and CEO of BionX. “Our new name helps communicate our commitment to offering bionic solutions that restore normalized limb function and improve quality of life. We are continually inspired by our patients who strive to achieve their greatest potential.”

The BiOM® Ankle, the company’s flagship product, is the only lower-limb prosthesis with powered propulsion for enhanced mobility. Only the BiOM Ankle provides power that emulates lost muscle function, control that mimics normal ankle movement and stability that automatically adjusts to any surface.

BionX is in the process of executing several key growth drivers including expanded insurance reimbursement, international commercial expansion and new product introductions.

About BionX™:

BionX is a leader in the field of prosthetic devices with their flagship product the BiOM Ankle, the only lower-limb prosthesis with powered propulsion for enhanced mobility. Privately held and headquartered in Bedford, Mass., BionX was originally founded in 2007 as iWalk by Dr. Hugh Herr, Director and Principal Investigator of the Biomechatronics Group of MIT’s Media Laboratory, and funded by leading investment firms including WFD Ventures, General Catalyst Partners, Sigma Partners, and Gilde Healthcare Partners. The company has also received funding and support from the U.S. Department of Veterans Affairs and the U.S. Army’s Telemedicine and Advanced Technology Research Center (TATRC).

About the BiOM® Ankle:

The BiOM Ankle leverages patented technology to address the limitations of current lower-limb prostheses. Only the BiOM Ankle provides power that emulates lost muscle function, control that mimics normal ankle movement and stability that automatically adjusts to any surface. Clinical studies have shown that the BiOM Ankle can help people to walk faster and farther with less energy, improve balance and stability, reduce joint forces that lead to pain and more easily climb ramps, hills and stairs.1-7

WWW.BIONXMED.COM

WWW.TRY-BIOM.COM

Mehr neuigkeiten

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
17. Oktober 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
15. Oktober 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
14. Oktober 2025